Although AraC remains the standard of care in first-line AML induction therapy, new targeted agents, such as BCL2-selective inhibitor venetoclax (ABT-199), were recently approved for AML treatment by EMA and FDA. This evidence concerns the gene BCL2 and acute myeloid leukemia.